Loading
companiesCompany
Zenith Epigenetics
Zenith Epigenetics is a Calgary biotech whose oral BET inhibitor ZEN-3694 is being tested with enzalutamide in castration-resistant prostate cancer and with PARP inhibitors and immunotherapy in other tumours.
Also called: Zenith Epigenetics Ltd.
Overview
Zenith Epigenetics, spun out of Resverlogix, develops ZEN-3694 (ZEN003694), an oral inhibitor of bromodomain and extra-terminal (BET) proteins that reduces transcription of MYC and androgen receptor-driven programmes. ZEN-3694 has been studied with enzalutamide in metastatic castration-resistant prostate cancer, including a randomised phase 2b trial, with talazoparib in triple-negative breast cancer, and with pembrolizumab, and is in a National Cancer Institute-sponsored trial in NUT carcinoma.
Headquarters
Calgary, CA
Scorecard
All companies#334of 1244 companies, score 12
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +7
0 approved, 0 in phase 3, 1 earlier, 1 targets, 12 registry studies. Formula on the scorecards page.
Type
Website
Phase 2Oral small-molecule BET bromodomain inhibitor
ZEN-3694 is a BET inhibitor from Zenith Epigenetics being tested in NUT carcinoma, where the cancer's driving fusion is itself a BET protein, and in prostate and breast cancers.
drugs
Phase 2Oral small-molecule BET bromodomain inhibitor